Drug disposition of incadronate, a new bisphosphonate, in rats with bone metastases.
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
1. Drug disposition of incadronate in the nude rat with bone metastases induced by A375 human melanoma cells was studied after intravenous administration. 2. The pharmacokinetics of incadronate (plasma concentration, urinary excretion and bone uptake) in rat with bone metastases was not markedly different from that in the control rat. This compound, however, was selectively taken up in the bone region around metastatic tumour nests. 3. Drug concentrations in the bone region around tumour nests were 3-10 micrograms/g, these levels being higher than the IC50 (0.35 microgram/ml) for the inhibitory effect of this drug on osteoclasts in vitro. 4. In contrast, concentrations in the tumour nest itself was < 0.7 microgram/g, being markedly lower than the IC50 (35 micrograms/ml) for the inhibitory effect on the proliferation of tumour cells in vitro. 5. These results strongly suggest that pharmacological action of incadronate in mouse with bone metastases (inhibitory effect on the growth of metastatic tumour in bone) is caused not by the direct action on the tumour cells but by the distribution of the drug in the perifocal bone region followed by inhibition of the activity of osteoclasts, resulting in inhibition of the osteolytic process, which is necessary for the progress of metastatic tumour.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the growth-inhibitory effects of incadronate on cultured tumor cells occurred at 100-fold higher concentrations than those needed to suppress osteoclasts.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [342]
In the citing paper
“animal data showing that the uptake of radiolabeled bisphosphonate was no greater in bones with extensive metastatic disease compared with tumor-free bones (342).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [342]
Citations
Cites
Drug Metabolism and Disposition
(2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12259_4 · Cited by 2,515
Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., & Rodan, G. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115539 · Cited by 1,004
Fleisch, H. (1991) · Drugs · doi:10.2165/00003495-199142060-00003 · Cited by 581
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Sasaki, A., Boyce, B. F., Story, B. M., Wright, K. R., Chapman, M., Boyce, R. W., Mundy, G. R., & Yoneda, T. (1995) · PubMed · Cited by 417
Xenobiotic metabolism and disposition
Chen, G. (2020) · An Introduction to Interdisciplinary Toxicology · doi:10.1016/b978-0-12-813602-7.00003-x · Cited by 152
Nakai, M., Mundy, G. R., Williams, P. J., Boyce, B. F., & Yoneda, T. (1992) · PubMed · Cited by 109
Hall, D. G., & Stoica, G. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090211 · Cited by 74
TAKEUCHI, M., SAKAMOTO, S., YOSHIDA, M., Tetsushi, A. B. E., & ISOMURA, Y. (1993) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.41.688 · Cited by 70
Inhibitory effects of bisphosphonate (YM175) on bone resorption induced by a metastatic bone tumor
Hiraga, T., Tanaka, S., Yamamoto, M., Nakajima, T., & Ozawa, H. (1996) · Bone · doi:10.1016/8756-3282(95)00428-9 · Cited by 66
Self-citationPathophysiology of Skeletal Complications of Cancer
Mundy, G. R., & Martin, T. J. (1993) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-77991-6_18 · Cited by 31
Research works printed but not linked: 5
- KAWAMUKI K., 1990, Journal of Bone and Mineral Research, 5, S245
- KUDO M., 1990, Journal of Bone and Mineral Research, 5, S166
- NAKAI M., 1992, Cancer Research, 52, 5395
- SASAKI A., 1995, Cancer Research, 55, 3551
- TAKAHASHI K., 1994, Clinical Report, 28, 2905
Cited by
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Hiraga, T., Williams, P. J., Mundy, G. R., & Yoneda, T. (2001) · PubMed · Cited by 256
Pan, B., Farrugia, A. N., To, L. B., Findlay, D. M., Green, J., Lynch, K., & Zannettino, A. C. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2004.19.1.147 · Cited by 157
Denoyelle, C., Hong, L., Vannier, J.-P., Soria, J., & Soria, C. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600925 · Cited by 158
Coxon, J. P., Oades, G. M., Kirby, R. S., & Colston, K. W. (2004) · British Journal of Urology · doi:10.1111/j.1464-4096.2004.04831.x · Cited by 140
Metadata
- Authors
- USUI*, T., TANAKA, S., SONODA, T., OZAWA, Y., TERAMURA, K., NAKAMURA, E., WATANABE, T., & HIGUCHI, S.
- Venue
- Xenobiotica
- Publisher
- Informa UK Limited
- Published
- 1997-01
- Volume
- 27
- Issue
- 5
- Pages
- 479-487
- ISSN
- 0049-8254 (ISSN-L)
- 1366-5928
- OpenAlex
- W2154858612
- Cited by
- 13
- References
- 14
- Citations by year
- 2013: 1
- FWCI
- 0.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Xenobiotica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- incadronate, bisphosphonates, drug disposition, pharmacokinetics, bone metastasis, A375 melanoma, osteoclast inhibition, osteolytic bone destruction, tumor growth inhibition
- MeSH terms
- Animals, Autoradiography, Bone Neoplasms, Cell Division, Diphosphonates, Half-Life, Male, Melanoma, Experimental, Metabolic Clearance Rate, Neoplasm Transplantation, Rats, Nude, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug disposition of incadronate, a new bisphosphonate, in rats with bone metastases. https://app.cochat.ai/papers/10.1080/004982597240442
- The paper
- USUI*, T., TANAKA, S., SONODA, T., OZAWA, Y., TERAMURA, K., NAKAMURA, E., WATANABE, T., & HIGUCHI, S. (1997). Drug disposition of incadronate, a new bisphosphonate, in rats with bone metastases. Xenobiotica. https://doi.org/10.1080/004982597240442
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.